Cargando…

No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration

Disease Activity Score in 28 joints (DAS28) is commonly used to evaluate disease activity of rheumatoid arthritis (RA) and is a guide to treatment decision. The aim of this study was to evaluate the impact of lower reporting limit for C-reactive protein (CRP), with respect to intraindividual biologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Inger M.J., Emamifar, Amir, Andreasen, Rikke A., Antonsen, Steen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228686/
https://www.ncbi.nlm.nih.gov/pubmed/28072726
http://dx.doi.org/10.1097/MD.0000000000005781
_version_ 1782493988495818752
author Hansen, Inger M.J.
Emamifar, Amir
Andreasen, Rikke A.
Antonsen, Steen
author_facet Hansen, Inger M.J.
Emamifar, Amir
Andreasen, Rikke A.
Antonsen, Steen
author_sort Hansen, Inger M.J.
collection PubMed
description Disease Activity Score in 28 joints (DAS28) is commonly used to evaluate disease activity of rheumatoid arthritis (RA) and is a guide to treatment decision. The aim of this study was to evaluate the impact of lower reporting limit for C-reactive protein (CRP), with respect to intraindividual biological variability, on the calculation of DAS28 and subsequent patient classification. This study consists of 2 sections: a theoretical consideration discussing the performance of CRP in calculating DAS28 taking intraindividual biological variation and lower reporting limit for CRP into account and a cross-sectional study of RA patients applying our theoretical results. Therefore, we calculated DAS28 twice, with the actual CRP values and CRP = 9 mg/L, the latter to elucidate the positive effects of reducing the lower reporting limit of CRP from <10 to <3 mg/L. Lower-reporting limit of <10 mg/L leads to overestimate DAS28. However, reducing lower reporting limit for CRP to <3 mg/L results in optimizing DAS28 calculation. Further lowering of reporting limit for CRP to <3 mg/L does not increase the precision of DAS28 owing to the relatively large intraindividual biological variation. Five hundred twelve patients were included. There was a significant difference between recalculated and patients DAS28 (P < 0.001). One hundred nine patients had DAS28 deviation (compatible to remission to low: 66, low to moderate: 39. and moderate to high: 4). Owing to significant impact of intraindividual biologic variation on DAS28 and patient classification, special attention should be paid to calculate DAS28 when CRP values are within normal range. Furthermore, we conclude that results of different studies evaluating DAS28 and treatment response are not comparable if the reporting limits of CRP are unknown.
format Online
Article
Text
id pubmed-5228686
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52286862017-01-25 No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration Hansen, Inger M.J. Emamifar, Amir Andreasen, Rikke A. Antonsen, Steen Medicine (Baltimore) 6900 Disease Activity Score in 28 joints (DAS28) is commonly used to evaluate disease activity of rheumatoid arthritis (RA) and is a guide to treatment decision. The aim of this study was to evaluate the impact of lower reporting limit for C-reactive protein (CRP), with respect to intraindividual biological variability, on the calculation of DAS28 and subsequent patient classification. This study consists of 2 sections: a theoretical consideration discussing the performance of CRP in calculating DAS28 taking intraindividual biological variation and lower reporting limit for CRP into account and a cross-sectional study of RA patients applying our theoretical results. Therefore, we calculated DAS28 twice, with the actual CRP values and CRP = 9 mg/L, the latter to elucidate the positive effects of reducing the lower reporting limit of CRP from <10 to <3 mg/L. Lower-reporting limit of <10 mg/L leads to overestimate DAS28. However, reducing lower reporting limit for CRP to <3 mg/L results in optimizing DAS28 calculation. Further lowering of reporting limit for CRP to <3 mg/L does not increase the precision of DAS28 owing to the relatively large intraindividual biological variation. Five hundred twelve patients were included. There was a significant difference between recalculated and patients DAS28 (P < 0.001). One hundred nine patients had DAS28 deviation (compatible to remission to low: 66, low to moderate: 39. and moderate to high: 4). Owing to significant impact of intraindividual biologic variation on DAS28 and patient classification, special attention should be paid to calculate DAS28 when CRP values are within normal range. Furthermore, we conclude that results of different studies evaluating DAS28 and treatment response are not comparable if the reporting limits of CRP are unknown. Wolters Kluwer Health 2017-01-10 /pmc/articles/PMC5228686/ /pubmed/28072726 http://dx.doi.org/10.1097/MD.0000000000005781 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 6900
Hansen, Inger M.J.
Emamifar, Amir
Andreasen, Rikke A.
Antonsen, Steen
No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration
title No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration
title_full No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration
title_fullStr No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration
title_full_unstemmed No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration
title_short No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration
title_sort no further gain can be achieved by calculating disease activity score in 28 joints with high-sensitivity assay of c-reactive protein because of high intraindividual variability of c-reactive protein: a cross-sectional study and theoretical consideration
topic 6900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228686/
https://www.ncbi.nlm.nih.gov/pubmed/28072726
http://dx.doi.org/10.1097/MD.0000000000005781
work_keys_str_mv AT hanseningermj nofurthergaincanbeachievedbycalculatingdiseaseactivityscorein28jointswithhighsensitivityassayofcreactiveproteinbecauseofhighintraindividualvariabilityofcreactiveproteinacrosssectionalstudyandtheoreticalconsideration
AT emamifaramir nofurthergaincanbeachievedbycalculatingdiseaseactivityscorein28jointswithhighsensitivityassayofcreactiveproteinbecauseofhighintraindividualvariabilityofcreactiveproteinacrosssectionalstudyandtheoreticalconsideration
AT andreasenrikkea nofurthergaincanbeachievedbycalculatingdiseaseactivityscorein28jointswithhighsensitivityassayofcreactiveproteinbecauseofhighintraindividualvariabilityofcreactiveproteinacrosssectionalstudyandtheoreticalconsideration
AT antonsensteen nofurthergaincanbeachievedbycalculatingdiseaseactivityscorein28jointswithhighsensitivityassayofcreactiveproteinbecauseofhighintraindividualvariabilityofcreactiveproteinacrosssectionalstudyandtheoreticalconsideration